Federated Hermes
CSTL icon

Federated Hermes’s Castle Biosciences CSTL Stock Holding History

Federated Hermes’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7K Sell
489
-760
-61% -$16.9K ﹤0.01% 1836
2026
Q1 		$30.7K Buy
1,249
+589
+89% +$19.3K ﹤0.01% 1737
2025
Q4 		$25.7K Buy
+660
New +$21.3K ﹤0.01% 1726
2025
Q1 		– Sell
-114
Closed -$3.04K – 2087
2024
Q4 		$3.04K Buy
+114
New +$3.47K ﹤0.01% 1941
2021
Q2 		– Sell
-139,747
Closed -$9.57M – 2229
2021
Q1 		$9.57M Sell
139,747
-136,852
-49% -$10.3M 0.02% 671
2020
Q4 		$18.6M Buy
276,599
+101,545
+58% +$5.5M 0.04% 490
2020
Q3 		$9.01M Buy
175,054
+34,609
+25% +$1.54M 0.02% 590
2020
Q2 		$5.29M Buy
140,445
+561
+0.4% +$19.2K 0.01% 703
2020
Q1 		$4.17M Buy
139,884
+137
+0.1% +$4.13K 0.01% 680
2019
Q4 		$4.8M Buy
139,747
+74,747
+115% +$1.83M 0.01% 786
2019
Q3 		$1.18M Buy
+65,000
New +$1.44M ﹤0.01% 1223

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's CSTL Position: Q2 2026 in Review

Federated Hermes reduced its Castle Biosciences (CSTL) stake by 61% in Q2 2026, selling an estimated $16.9K and leaving 489 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1836.

Federated Hermes first reported a position in CSTL in Q3 2019 and has held it in 11 quarters since. The position peaked at $18.6M in Q4 2020. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Federated Hermes held 489 shares of Castle Biosciences worth $11.7K as of Q2 2026.
  • Federated Hermes sold 760 Castle Biosciences shares in Q2 2026, an estimated $16.9K.
  • Castle Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1836 holding.
  • Federated Hermes first reported a position in Castle Biosciences in Q3 2019 and has held it in 11 quarters since.
  • Federated Hermes's Castle Biosciences position peaked at $18.6M in Q4 2020.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.